The Evoke System instantaneously reads, records, and responds to the nerves' response to stimulation to provide continually optimized therapy and is proven to be superior to open-loop SCS for the treatment of overall trunk and/or limb pain. 12-month results from the EVOKE Study, the first double-blind randomized controlled trial (RCT) used in support of Premarket Approval (PMA) in spinal cord stimulation history, were published in The Lancet Neurology and 24-month results have since been published JAMA Neurology. Saluda Medical's latest funding was a Series F round on October 30, 2025, positioning the company for expanded commercialization.
Cyborg Score Rationale
Published clinical evidence in top-tier journals demonstrates superiority and long-term pain relief improvements, with $530M in funding from major investors like Boston Scientific. As of April 30, 2026, the company has 483 employees, enabling scaled execution. Remaining challenge: revenue of $20.2 million in 2026 reflects early commercialization stage in a significant market.
Top Insights
First RCT-based PMA approval in spinal cord stimulation history, with results published in leading neurology journals
Evoke System automatically adjusts stimulation over 4 million times per day based on real-time neural signals, delivering personalized therapy
CE Marked and commercially available in EU; FDA-approved in US with commercial expansion underway
$530M total funding with participation from established medtech investors including Boston Scientific
Named Competitors
Nalu Medical — Neuromodulation and pain management
Abbott Pain Management — Open-loop spinal cord stimulation systems
Boston Scientific Pain Management — Spinal cord stimulation and neuromodulation
Nevro — High-frequency spinal cord stimulation systems
Medtronic — Spinal cord stimulation and neuromodulation devices
Recent Developments
(October 2025) Series F funding round completed, supporting commercial expansion
(April 2026) Employee count reached 483, indicating scaling of sales and operations
(March 2026) Continued commercialization of Evoke System in US market
Open the full interactive Saluda Medical report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.